FDA Accepts NDA for Exelixis' Zanzalintinib-Atezolizumab Combination

TokenomicsTherapist · 2026-03-04T06:09:01+00:00

Exelixis has received FDA approval for its NDA on a combination therapy for advanced colorectal cancer, pairing zanzalintinib and atezolizumab. This follows positive clinical trial results and marks a significant milestone for the company's oncology candidates.

TokenomicsTherapist

2026-03-04 06:09:01

Abstract generation in progress

Exelixis has reached a significant regulatory milestone as the FDA greenlit its New Drug Application for a combination therapy targeting advanced colorectal cancer. The dual-agent approach pairs zanzalintinib, a tyrosine kinase inhibitor, with the immunotherapy atezolizumab—marking the company’s first NDA submission for this novel oncology candidate.

Regulatory Pathway and Treatment Eligibility

The FDA cleared the NDA for review under a standard timeline, with a PDUFA target action date set for December 3, 2026. This designation covers the treatment of adult patients with metastatic colorectal cancer who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy regimens. Additionally, for patients with RAS wild-type tumors, prior anti-EGFR therapy is required.

Clinical Foundation and Development

The regulatory filing is underpinned by positive data from the phase 3 STELLAR-303 pivotal trial, which evaluated the combination therapy’s efficacy in this heavily pretreated patient population. Dana Aftab, Executive Vice President of Research and Development at Exelixis, stated the company’s readiness to work closely with the FDA throughout the review process for this landmark oncology NDA.

Market Response

Exelixis shares responded positively to the announcement, climbing 0.75% to $41.67 in pre-market trading on NasdaqGS, reflecting investor confidence in the company’s advancement in colorectal cancer therapeutics.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes